Up­dat­ed: Lil­ly boosts sales guid­ance by $2B, but GLP-1 sup­ply con­straints still a fo­cus

Eli Lil­ly is ex­pect­ing sup­ply dis­rup­tions for its block­buster weight loss and di­a­betes prod­ucts to con­tin­ue through the end of this year, ex­ec­u­tives told in­vestors.

Dur­ing its first-quar­ter earn­ings call on Tues­day, the com­pa­ny said it’s rapid­ly ex­pand­ing its man­u­fac­tur­ing ca­pac­i­ty, with six sites cur­rent­ly un­der con­struc­tion or ramp­ing up, and a sev­enth it re­cent­ly pur­chased. CFO Anat Ashke­nazi ex­pects Lil­ly to pro­duce 1.5-times more dos­es of its in­cretin med­i­cines in the sec­ond half of 2024 com­pared to the same pe­ri­od in 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER